glp 1 use in pregnancy GLP-1 during early may not increase risk of major adverse outcomes Target trial does not suggest

LH/FSH, luteinizing hormone/follicle-stimulating hormone ratio

Every day movements feel easier

The key findings from this clinical program include significant reductions in body weight and fat mass in treatment groups compared to placebo, preferential loss of abdominal and visceral adipose tissue, no changes in serum IGF-1 levels at any dose tested, no negative effects on glucose metabolism or insulin sensitivity, no significant adverse events related to metabolic or endocrine disruption, and safety profile indistinguishable from placebo for most parameters

For best results, it is recommended to wear PatchAid patches for 8 hours